CSIMarket Company Name, Ticker, Competitors, else..
 
Cvrx inc   (NASDAQ: CVRX)
Other Ticker:  
 
 
Price: $6.8500 $0.51 8.044%
Day's High: $6.9 Week Perf: 25.92 %
Day's Low: $ 6.08 30 Day Perf: 4.9 %
Volume (M): 400 52 Wk High: $ 18.55
Volume (M$): $ 2,739 52 Wk Avg: $10.91
Open: $6.21 52 Wk Low: $4.30



 Market Capitalization (Millions $) 177
 Shares Outstanding (Millions) 26
 Employees 200
 Revenues (TTM) (Millions $) 53
 Net Income (TTM) (Millions $) -52
 Cash Flow (TTM) (Millions $) 23
 Capital Exp. (TTM) (Millions $) 1

Cvrx Inc
CvRx Inc. is a medical device company based in Minneapolis, Minnesota. It specializes in developing implantable technologies for the treatment of cardiovascular diseases. The company's main product is the BAROSTIM NEO System, which is an implantable device that delivers electrical signals to the baroreceptors in the carotid sinus. This therapy helps to regulate blood pressure and improve cardiac function in patients suffering from hypertension or heart failure. CvRx Inc. has gained recognition for its innovative approach to cardiovascular care and is dedicated to improving patient outcomes and quality of life.


   Company Address: 9201 West Broadway Avenue Minneapolis 55445 MN
   Company Phone Number: 416-2840   Stock Exchange / Ticker: NASDAQ CVRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BAX        3.59% 
BDX        3.01% 
EW        3.36% 
IART        0.3% 
MMSI        0.5% 
TFX        1.41% 
• View Complete Report
   



Product Service News

CVRx Highlights Barostims Quality of Life Benefits Amidst Year-to-Date Stock Struggles,

Published Thu, Sep 12 2024 12:00 PM UTC

CVRx Publishes New Data Showcasing Long-Term Quality of Life Benefits of Barostim in Heart Failure Patients CVRx Inc. (NASDAQ: CVRX) has announced the publication of new data highlighting the long-term benefits of its innovative Barostim therapy, which offers promising quality of life enhancements for patients suffering from heart failure with reduced ejection fraction. The ...
Product Service News

CVRx Secures Increased Inpatient Payment for Barostim Procedure A Game Changer in Heart Failure Treatment

Published Fri, Aug 2 2024 12:00 PM UTC

In a significant development for the cardiovascular medical device landscape, CVRx, Inc. (NASDAQ: CVRX) announced on August 2, 2024, that the Centers for Medicare and Medicaid Services (CMS) has redefined payment parameters for the Barostim implant procedure, marking a crucial milestone for hospital reimbursement under the Fiscal Year (FY) 2025 Medicare Hospital Inpatient Pr...
Cvrx Inc

Despite Revenue Boost, Company Falls Short of Profitability Goals in Q1 2024

Cvrx Inc, a medical device company focused on cardiovascular diseases, has recently experienced a significant drop in its stock price. Over the past five trading days, the company's stock has declined by 39.66%, bringing the share price to a total decrease of 48.69% during the second quarter of 2024. Additionally, Cvrx's stock currently trades only 18.7% above its 52-week low.
The company is set to release its first-quarter 2024 financial and operating results on April 30th, after the market closes. This announcement will provide crucial insights into the company's performance and may shed light on the reasons behind the recent decline in stock price. Investors and stakeholders can gain a better understanding of Cvrx's financial health and strategies through the analysis of these results.
Clinical Study

Barostim Therapy: A Promising Approach for Heart Failure Management

Published Mon, Apr 15 2024 11:30 AM UTC

Heart failure affects millions of individuals worldwide and is associated with significant morbidity and mortality rates. Despite advances in medical management, many patients experience persistent symptoms and reduced quality of life. However, recent data from the BeAT-HF trial and abstracts presented at the THT conference suggest that Barostim Therapy holds promise as an i...
Cvrx Inc

Cvrx Inc experiences impressive 70.805% surge in revenue during October-December 2023 period

CVRx Inc, a commercial-stage medical device company specializing in developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, recently announced its financial and operating results for the fourth quarter and full year of 2023. The company also achieved FDA approval for expanded labeling of its Barostim therapy, marking a significant milestone in cardiac healthcare.
In terms of financial performance, CVRx Inc reported a shortfall per share of $-0.44 per share for the financial interval closing December 31, 2023. This represents an increase compared to $-0.26 per share in the previous year and a growth in shortfall from $-0.43 per share from the previous reporting season. However, it's worth noting that the company's revenue saw a strong increase of 70.805% to $12.26 million from $7.18 million in the corresponding reporting season a year ago. Sequentially, revenue improved by 24.817% from $9.82 million.






Cvrx Inc's Segments
U S    90.98 % of total Revenue
Other countries    9.31 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com